tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Argenx’s Promising Phase 2 Study on Efgartigimod PH20 SC for Systemic Sclerosis

Argenx’s Promising Phase 2 Study on Efgartigimod PH20 SC for Systemic Sclerosis

Argenx ((ARGX)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Argenx is conducting a clinical study titled ‘A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis.’ The study aims to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis, a condition with limited treatment options. This research is significant as it could lead to a new therapeutic option for patients suffering from this debilitating disease.

The intervention being tested is efgartigimod PH20 SC, a combination product administered subcutaneously via a prefilled syringe. It is designed to modulate the immune system and potentially alleviate symptoms of systemic sclerosis.

The study is interventional, with participants randomly assigned to either the efgartigimod PH20 SC group or a placebo group in a 2:1 ratio. It employs a parallel intervention model with quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.

The study began on November 11, 2024, with the most recent update submitted on July 22, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.

This study update could positively influence Argenx’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio and market position. In the competitive landscape of autoimmune disease treatments, advancements in systemic sclerosis therapy could set Argenx apart from its competitors.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1